Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases

Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases

US Patent 10745486 · Granted Aug 18, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Chimeric antigen receptor and CAR-T cells that bind BCMA2025
Chimeric antigen receptor and CAR-T cells that bind BCMA2025
Extracorporeal devices for methods for treating diseases associated with anti-ne2024
Chimeric antigen receptor and CAR-T cells that bind BCMA2024
Chimeric antigen receptor and CAR-T cells that bind BCMA2024
Humanized antibodies against CD269 (BCMA)2023
Humanized antibodies against CD269 (BCMA)2023
Humanized antibodies against CD269 (BCMA)2023
Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cel2023
Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cel2023
Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cel2023
Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cel2023